Head and Neck Cancer Trial, Recruiting NCT03238378 Sponsor: University of Erlangen-Nürnberg Medical School Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Head and Neck Cancer Trial, Recruiting

NCT03238378
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have a head and neck cancer that has come back (recurred), confirmed by a tissue sample analysis
  • People whose returning cancer is classified as an early-to-intermediate stage (rcT1-3, meaning the tumour is not the most advanced size)
  • People whose tumour is located in a position that makes a specific internal radiation treatment (brachytherapy) physically possible
  • People with no cancer spread to nearby lymph nodes, or who have had lymph nodes removed with clean margins and no more than 2 affected lymph nodes without the cancer breaking through the lymph node's outer layer
  • People with no cancer spread to distant parts of the body (M0)
  • People who are reasonably well and able to carry out daily activities (rated 0–2 on a standard medical performance scale)
  • People who previously received radiation therapy of at least 50 Gy (a standard unit of radiation dose)
  • People whose previous radiation therapy was completed more than 6 months ago
  • People who have provided written consent to participate in the study

Who may not be able to join:

  • People whose cancer is classified as the most advanced local stage (cT4)
  • People who have more than 2 affected lymph nodes, or whose cancer has broken through the outer layer of a lymph node
  • People who are pregnant or breastfeeding
  • People who have a connective tissue disease (a condition affecting the body's structural tissues)
  • People who have an inherited condition that makes them unusually sensitive to radiation, such as Ataxia Telangiectasia or similar conditions
  • People who have a psychiatric disorder

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Vratislav Strnad, MD, Dept. of Radiation Therapy, University Hospital Erlangen

Phone: ++49 9131 85

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Erlangen-Nürnberg Medical School
Registry
ClinicalTrials.gov
Start date
29 March 2017
Est. completion
31 December 2022

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Late side effects

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov